Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City
April 24 2019 - 8:00AM
Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST –
TSX-V: ACST), a biopharmaceutical innovator focused on the
research, development and commercialization of its prescription
drug candidate CaPre® (omega-3 phospholipid) for the treatment of
severe hypertriglyceridemia (HTG), today announced that Jan
D'Alvise, President and Chief Executive Officer, is scheduled to
present at the ThinkEquity Conference on Thursday, May 2nd, at 3:00
PM Eastern Time, which is being held at The Mandarin Oriental Hotel
in New York City.
Additional information on the conference is
available at,
https://www.think-equity.com/thinkequity-conference
About CaPre (omega-3
phospholipid)
Acasti Pharma’s prescription drug candidate,
CaPre, is a highly purified omega-3 phospholipid concentrate
derived from krill oil and is being developed to treat severe
hypertriglyceridemia, a metabolic condition that contributes to
increased risk of cardiovascular disease and pancreatitis. Its
omega-3s, principally EPA and DHA, are either “free” or bound to
phospholipids that allows for better absorption into the body.
Acasti Pharma believes that EPA and DHA are more efficiently
transported by phospholipids sourced from krill oil than the EPA
and DHA contained in fish oil that are transported either by
triglycerides (as in dietary supplements) or as ethyl esters in
other prescription omega-3 drugs, which must then undergo
additional digestion before they are ready for transport in the
bloodstream. Acasti Pharma’s CaPre Phase 3 program is currently
underway.
About Acasti Pharma
Acasti Pharma is a biopharmaceutical innovator
advancing a potentially best-in-class cardiovascular drug, CaPre®
(omega-3 phospholipid), for the treatment of hypertriglyceridemia,
a chronic condition affecting an estimated one third of the U.S.
population. Since its founding in 2008, Acasti Pharma has focused
on addressing a critical market need for an effective, safe and
well-absorbing omega-3 therapeutic that can make a positive impact
on the major blood lipids associated with cardiovascular disease
risk. Acasti Pharma is developing CaPre in a Phase 3 clinical
program in patients with severe hypertriglyceridemia, a market that
includes 3 to 4 million patients in the U.S. The addressable market
may expand significantly if omega-3s demonstrate long-term
cardiovascular benefits in on-going third-party outcomes studies.
Acasti Pharma may need to conduct at least one additional clinical
trial to support FDA approval of a supplemental New Drug
Application to expand CaPre’s indications to this segment. Acasti
Pharma’s strategy is to commercialize CaPre in the U.S. and Acasti
Pharma is pursuing development and distribution partnerships to
market CaPre in major countries around the world. For more
information, visit www.acastipharma.com.
Acasti Contact:Jan D’Alvise, President and
Chief Executive Officer Tel: 450-686-4555 Email:
info@acastipharma.comwww.acastipharma.com
Investor Contact:Crescendo Communications,
LLCTel: 212-671-1020Email: ACST@crescendo-ir.com
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Sep 2023 to Sep 2024